← Oncology Approval Tracker

FDA DECISION ·

Xalkori

crizotinib · Pfizer

FDA approvalNew or expanded indicationAnaplastic large cell lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Children age 1 and older and young adults with ALK-positive systemic anaplastic large cell lymphoma that relapsed or resisted treatment.

LAMPGEN ANALYSIS

Why it matters

The decision extends an ALK inhibitor from lung cancer into a distinct pediatric and young adult lymphoma population.

What research teams should watch

Confirm ALK status, systemic disease, age and prior treatment response at screening.

PRIMARY RECORDS

Sources